-
Broad-spectrum anti-tumor!
Time of Update: 2022-01-12
BGC0228 replaces the antibody with a polymer target head, and forms a new compound through peptide chain combined with traditional cytotoxic drugs, which achieves precise connection without falling off, and has a smaller molecular weight than ADC drugs, so that it can smoothly penetrate tumor cells and release drugs into tumor cell tissues.
-
ASKC202, a subsidiary of Aosaikang, obtained the notification of acceptance of clinical trial application
Time of Update: 2022-01-12
ASKC202 tablet is a Class 1 new drug with independent intellectual property rights, and is a potent and highly selective oral small molecule c-MET inhibitor .
Resistance, MET gene amplification occurs in 5%-22% of EGFR inhibitor-resistant non-small cell lung cancer patients .
-
Fangsheng Pharmaceutical’s Xuanqijian Bone Tablet was approved and issued by the State Drug Administration as the "Drug Registration Certificate"
Time of Update: 2022-01-12
On December 7, Fangsheng Pharmaceutical issued an announcement stating that it had recently received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration.
It is used to improve the symptoms of mild to moderate knee osteoarthritis in TCM syndrome, which is the syndrome of musculoskeletal stasis.
-
The State Food and Drug Administration cancels the registration certificate of disposable infusion set with needle medical device
Time of Update: 2022-01-12
On December 1, the State Food and Drug Administration issued an announcement stating that, in accordance with the Regulations on the Supervision and Administration of Medical Devices, the medical devi
-
Hengrui Medicine's new drug for dry eye disease successfully plans to be reported for listing in Phase III clinical trials
Time of Update: 2022-01-12
On November 30, Hengrui Medicine announced that SHR8058 eye drops for the treatment of meibomian gland dysfunction-related dry eye disease is a multi-center, randomized, double-blind, salt solution parallel controlled phase III clinical trial (SHR8058-301) that has achieved the main research endpoint results.
-
TOP20 retail Chinese patent medicinal plasters released, 4 products rose by over 30%, 11 brands with over 100 million dazzling
Time of Update: 2022-01-12
Xiaotong plaster hits a new high, Lingrui's 6 major brands are eye-catchingXiaotong plaster hits a new high, Lingrui's 6 major brands are eye-catchingSales of terminal pain relief plasters in physical pharmacies in Chinese cities in recent years (unit: 100 million yuan)Source: Mi Nei. com, China's urban physical pharmacy terminal competition patternXiaotong Plaster is the exclusive product of Tibet Qizheng Tibetan Medicine.
-
Zhimeng Pharmaceutical's TLR8 agonist obtains FDA clinical trial approval
Time of Update: 2022-01-11
Source: Guanlan PharmaceuticalRecently, Zhimeng Pharmaceutical announced that the US FDA has approved the clinical trial application of its small molecule oral TLR8 agonist CB06-036 .
As a TLR8 agonist, CB06-036 has shown good selectivity, activity and safety in preclinical studies.
-
Decei Pharma and Bristol-Myers Squibb will jointly promote the clinical development of ATG-017 and Odivo
Time of Update: 2022-01-11
HK) today announced that the company and Bristol-Myers Squibb have reached a clinical cooperation agreement to jointly develop a joint evaluation of ATG-017 and Bristol-Myers Bristol-Myers Squibb's PD-1 checkpoint inhibitor Odivo® (Navulimab) is an open phase 1/2 clinical study on the safety, pharmacokinetics and preliminary efficacy of the treatment of advanced solid tumors .
-
Novartis' long-acting lipid-lowering siRNA therapy twice a year is approved by the FDA for marketing
Time of Update: 2022-01-11
Article Source: Immediate Medicine NewsOn December 23, Novartis announced that the US FDA has approved Leqvio (inclisiran), which is currently the first and only one for lowering low-density lipoprotein cholesterol (also known as "bad cholesterol" or LDL-C).
Retrieved 2021-12-23, from https:// -releases/fda-approves-novartis-leqvio-inclisiran-first-in-class-sirna-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year-301450125.
-
The first-line standard treatment of lymphoma can not be shaken for 20 years?
Time of Update: 2022-01-11
At the 2021 ASH Annual Meeting held recently, Vibotuzumab combined with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) compared with R-CHOP (rituximab) , Cyclophosphamide, doxorubicin, vincristine, prednisone) in the first-line treatment of diffuse large B-cell lymphoma (DLBCL) phase III POLARIX study as the "latest breakthrough study (LBA-1)" released detailed data, and Simultaneously published in NEJM[1] .
-
Good news for patients with chronic diseases!
Time of Update: 2022-01-11
In response to relevant national policies, we are committed to enabling more Chinese patients to benefit from high-quality innovative drugs, providing adequate guarantees for standardized treatment of chronic diseases, and helping to achieve'Healthy China 2030' .
-
Three types of imitation inhalants of Jiming Trust are accepted by CDE
Time of Update: 2022-01-11
In 2019, Wang Chen, an academician of the Chinese Academy of Engineering and an expert in respiratory and critical care medicine, published research results in The Lancet, clarifying the prevalence of adult asthma in China: the prevalence of asthma in people aged 20 and above in China is 4.
-
Pfizer's JAK1 inhibitor abrocitinib is approved in the EU for the treatment of moderate to severe atopic dermatitis
Time of Update: 2022-01-11
The JADE COMPARE trial is a randomized, double-blind, placebo-controlled study designed to evaluate two doses of Cibinqo (100 mg and 200 mg once a day) in 837 adults with moderate to severe atopic dermatitis in background topical medications In the efficacy and safety .
-
The registration of Artemisia annua pollen prickly liquid medicine has been accepted
Time of Update: 2022-01-11
On December 22, our company issued an announcement stating that it had obtained the "Notice of Acceptance" issued by the National Medical Products Administration a few days ago, and the company's regi
-
Shaoxing City, Zhejiang Province issued an emergency notice to suspend the sale of "category four" drugs in various pharmacies in the city
Time of Update: 2022-01-11
Coincidentally, Ningbo, Zhejiang Province initiated Level I emergency response on December 7, and various regions demanded that all pharmacies suspend the sale of "category four" drugs and implement the "removal of the shelf" treatment .
-
Can Hengrui fight the PD-1 again?
Time of Update: 2022-01-11
On the same day, Hengrui Medicine registered a phase 1 clinical trial on the drug clinical trial registration and information disclosure platform website for subcutaneous injection of PD-1 antibody SHR-1901 .
PD-1/PD-L1 competition is upgraded again!Source: Drug Clinical Trial Registration and Information Disclosure PlatformSHR-1901 is the second PD-1 antibody developed by Hengrui Pharmaceuticals.
-
Zuoli Pharmaceutical Polycarbophil Calcium Tablets Obtained Drug Registration Certificate
Time of Update: 2022-01-11
On December 9, Zuoli Pharmaceuticals issued an announcement stating that the company received the "Drug Registration Certificate" for polycarbophil calcium tablets approved and issued by the National Medical Products Administration for the relief of patients with irritable bowel syndrome (constipation).
-
Overcome resistance!
Time of Update: 2022-01-11
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn December 15th, Nuvation announced that the US FDA has granted the company's CDK2/4/6 inhibitor NUV-422 fast track designation for the treatment of high-grade gliomas, including glioblastoma multiforme .
-
The seventh batch of 87 nationally sourced varieties meet the conditions (list attached)
Time of Update: 2022-01-11
According to statistics from Huazhao Medical Network, in terms of product names, there are currently about 585 drugs that have been evaluated for consistency, of which about 63.
com, among the 3508 applications for consistency evaluation of generic drugs currently accepted, oral regular-release dosage forms and injections account for 47.
-
Hansen Pharma's high-priced broad-spectrum antifungal drug was approved for Phase III clinical trials
Time of Update: 2022-01-11
In June 2021, ibrexafungerp (trade name: Brexafemme) was approved by the US FDA for the treatment of vulvovaginal candidiasis, becoming the first new antifungal approved in more than two decades, and the first and only vagina Non-azole therapy for yeast infections .
